The study aims to compare efficacy and adverse reactions of hepatocellular carcinoma participants (≤5cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.
Study Type
OBSERVATIONAL
Enrollment
330
The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.
The Fifth Medical Center of PLA General Hospital (Beijing 302 hospital)
Beijing, China
RECRUITINGOverall survival rates
OS is calculated starting from the date of SBRT to the date of the final follow-up or demise of the patients.
Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months
Progression-free survival rates
PFS is estimated starting from the date of SBRT to the date of disease progression or patient death.
Time frame: From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 36 months
Local control rates
LC is defined starting from the date of SBRT to the date of treated-lesion progression or patient death.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
Radiation-induced liver injury rates
Time frame: From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.
Adverse reaction
Time frame: From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.